This work aimed to evaluate the use of optical coherence tomography (OCT) to guide the drug-eluting stent implantation during primary angioplasty. 201 patients experiencing STEMI to use or not OCT during primary angioplasty were randomized. The clinical and angiographic characteristics were well balanced, and no differences in MACE, cardiac death, TLR, or stent thrombosis at...
Spanish-Portuguese multicentre CIBELES study (Raul Moreno, Madrid, Spain) compared two drug-eluting stents – an everolimus (Xience V, Abbott Vascular, USA) and a sirolimus-releasing eluting stent (Cypher Select, Cordis Corporation, Miami Lakes, Florida, USA) in the context of total chronic coronary occlusions. With a non-inferiority design, the study randomized 208 patients (1:1), using as the primary...
Background: The ADAPT-DES registry showed a strong correlation between hypo-responders to clopidogrel and the likelihood of stent thrombosis at 30 days, while the impact of aspirin response has not been evaluated so far. This presentation focuses on the aspirin response impact in the clinical course of one year. Methods and Results: A total of 8,583...
Given the individual variability of response to antiplatelet therapies, measuring platelet function and designing tailored therapies could be beneficial. The ARTIC study tested the superiority of bedside platelet function monitoring with drug adjustment vs. the conventional post DES therapy without monitoring and drug adjustment. It included 2466 patients with stable coronary disease or Non-ST Elevation...
Coronary angioplasty in patients with kidney failure is associated with an increased occurrence of events. This study compared the efficacy of preventing clinical restenosis using an everolimus-eluting stent versus a conventional stent, both implanted in the same patient with lesions in more than one vessel and suffering from kidney failure. The primary endpoint was target...
Late endothelialization of first generation pharmacological stents may predispose thrombosis. Both the drug and the polymer of the platform may affect the rate at which this occurs. This is a prospective, multicenter study which randomized 44 patients with acute coronary syndrome to receive sirolimus-eluting stent with bio-absorbable polymer versus zotarolimus-eluting stent with permanent polymer. The...
There is still concern about the safety of drug-eluting stents (DES) due to the possibility of late and very late thrombosis. Dual antiplatelet aggregation for a year is recommended for patients receiving DES. The objective of this study was to test the non-inferiority of a new drug-eluting stent in terms of endothelial coverage after 3...
This study is still in progress and includes patients using SYNTAX II score based on functional invasive evaluation with iFR / FFR and performing angioplasty guided by IVUS using the biodegradable polymer everolimus eluting stent. The study seeks to prove superiority versus the first generation paclitaxel-eluting stent and non-inferiority versus surgery using historical data. We...
Currently the recommendation is 12 months of dual antiplatelet after a drug-eluting stent angioplasty. This study compared the 3 – months versus 12 months of dual antiplatelet after angioplasty with zotarolimus-eluting stent in real-world patients. This was a prospective, multicenter study randomized 1563 patients to receive aspirin and clopidogrel for 3 months and 1556 to...
This study randomized 1:1, 906 patients to receive zotarolimus-eluting stent and 905 patients to receive everolimus-eluting stent. The clinical and angiographic characteristics of both groups were similar with approximately 45% of the population experiencing an acute coronary syndrome. There were no significant differences in major cardiac events between the two stents with 6.1% to for...